Business & Industry
Pfizer to Acquire Metsera in a $10bn Deal as Board Backs
The news of Pfizer to acquire Metsera in a $10bn deal has indeed caught the eye of many. Metsera happens to be a US-based biotechnology firm and the deal was indeed a result of a heated bidding battle against...
BioPharma
Sofinnova Partners Raises $750mn to Support Biotech Startups
European venture capital firm Sofinnova Partners said on November 17 that it raised 650 million euros, equivalent to $750 million, for a new fund that is going to support the present and upcoming life sciences companies.
It is well to be...
Business & Industry
J&J Buys Halda for $3bn to Own the Cell Death Platform
Johnson & Johnson will be paying $3.05 billion so as to acquire Halda Therapeutics, thereby getting a novel cell death platform while at the same time also strengthening its prostate cancer franchise that’s built on Erleada.
At the mainstay of the...
News
Pharma Grade Supplements vs. Food Grade Supplements
In recent years, dietary supplements have become a major part of many people’s daily routines. From multivitamins and protein powders to herbal extracts and minerals, supplements are used to support health, fill nutritional gaps, and enhance overall wellbeing. However,...
News
Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing
Governor Jenniffer A. González Colón, along with Sebastián Negrón Reichard, the Economic Development and Commerce Secretary, has announced that Eli Lilly and Company, also known as Lilly, is going to invest over $1.2bn to modernize Puerto Rico operations. This...
BioPharma
FDA Looking to Lower Drugs Cost for All Americans
The Food and Drug Administration is looking to speed the development when it comes to biosimilars and has announced new guidelines, which would no longer want the makers of copycat biologics to indulge in human trials, therefore showing that...
BioPharma
GSK Licences COPD Drug from Empirico for $85 Million Upfront
In just a space of 24 hours, GSK, in its second pipeline-expanding deal, has gone on to license the rights to a drug for chronic obstructive pulmonary disease – COPD from Empirico, the US biotech, for $85 million, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.